NCI-2022-01554

A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab orStandard Therapies Including Chemotherapy and/or Immunotherapy in Participants with LocallyAdvanced or Metastatic Solid Tumors

This Phase 1/2 clinical trial is studying a new investigational drug called ASP1570 to evaluate its safety, tolerability, and potential effectiveness in people with locally advanced or metastatic solid tumors—cancers that cannot be removed completely by surgery or have spread to other parts of the body. Immune checkpoint inhibitors (like Pembrolizumab) have improved outcomes for many cancers by “releasing the brakes” on T‐cells. However, many tumors either don’t respond or become resistant. ASP1570 may help overcome that resistance by targeting a different immune-signaling node (DGKζ) and reviving T-cell responses in immune-suppressed tumors. Overall, the trial aims to determine whether ASP1570 can enhance existing treatments like pembrolizumab or chemotherapy, offering a new therapeutic option for patients with advanced cancers that have few remaining treatment choices.

Phase 1/2: Early phase (phases I and II) studies help researchers determine: Whether a new treatment is safe, what its side effects are and the best dose of the new treatment.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05083481

Clinical Trial Site: Columbia

To see all available clinical trials click here.